RESUMO
Se presenta el caso de un varón prematuro y con cardiopatía congénita de 4 meses de edad que presentaba unas bronquiolitis y conjuntivitis causadas por CI Metapneumovirus humano. El virus se detectó tanto en el aspirado nasofaríngeo como en la secreción conjuntival. Debido a la rareza de esta entidad, se revisa la literatura correspondiente a esta entidad (AU)
A premature male with congenital heart disease and 4 months of age had a bronchiolitis and conjunctivitis caused by human metapneumovirus. The virus was detected in both the nasopharyrngeal aspirate as coniunctival secretion. Because of the rarity of this entity we reviewed scientific literature (AU)
Assuntos
Humanos , Masculino , Lactente , Conjuntivite Viral/complicações , Conjuntivite Viral/diagnóstico , Conjuntivite Viral/etiologia , Conjuntivite/complicações , Conjuntivite/virologia , Metapneumovirus , Metapneumovirus/imunologia , Metapneumovirus/isolamento & purificação , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Doenças do Prematuro/diagnóstico , Bronquiolite/complicações , Bronquiolite/diagnóstico , Bronquiolite/terapia , Hospitalização/estatística & dados numéricos , Hospitalização/tendências , Tempo de Internação/tendênciasRESUMO
OBJECTIVES: To determine the frequency and types of respiratory viruses circulating in Boston long-term care facilities (LTCFs) during a 3-year period. DESIGN: Observational. SETTING: Thirty-three Boston-area LTCFs over a 3-year period. PARTICIPANTS: Residents of long-term care who had previously participated in a trial of vitamin E supplementation and had paired serum samples available for viral analysis. MEASUREMENTS: Viral antibody titers to eight respiratory viruses (influenza A and B, respiratory syncytial virus (RSV), parainfluenza virus serotype three (PIV-3), PIV-2, human metapneumovirus (hMPV), and coronaviruses 229E and OC43) were measured using enzyme immunoassay at baseline and 53 weeks. Infection was defined as a more than quadrupling of viral titers. Clinical data on respiratory illnesses were collected throughout the study period. RESULTS: A total of 617 persons were enrolled in the trial. Of these, 382 (62%) had sera available for viral analysis. A total of 204 viral infections were documented in 157 subjects. Serological responses to all eight viruses were documented, with hMPV (12.8%) and coronavirus 229E (10.5%) being the most common and PIV-2 (2.4%) the least common. The occurrence of bronchitis (P=.007), pneumonia (P=.02), and any lower respiratory tract infection (P=.002) was significantly associated with having a viral diagnosis. CONCLUSION: A wide range of respiratory viruses cocirculates in LTCFs and contributes to respiratory illness morbidity in these populations.
Assuntos
Anticorpos Antivirais/sangue , Casas de Saúde , Infecções Respiratórias/virologia , Vírus/isolamento & purificação , Idoso , Idoso de 80 Anos ou mais , Boston/epidemiologia , Feminino , Humanos , Técnicas Imunoenzimáticas , Assistência de Longa Duração , Masculino , Metapneumovirus/imunologia , Metapneumovirus/isolamento & purificação , Metapneumovirus/patogenicidade , Infecções por Paramyxoviridae/epidemiologia , Infecções Respiratórias/epidemiologia , Vírus/patogenicidadeRESUMO
The ability of the avian pathogen Mycoplasma gallisepticum to persist despite fluoroquinolone treatment was investigated in chickens. Groups of specific pathogen free chickens were experimentally infected with M. gallisepticum and treated with enrofloxacin at increasing concentrations up to the therapeutic dose. When M. gallisepticum could no longer be re-isolated from chickens, birds were stressed by inoculation of infectious bronchitis virus or avian pneumovirus. Although M. gallisepticum could not be cultured from tracheal swabs collected on several consecutive sampling days after the end of the enrofloxacin treatments, the infection was not eradicated. Viral infections reactivated the mycoplasma infection. Mycoplasmas were isolated from tracheal rings cultured for several days, suggesting that M. gallisepticum persisted in the trachea despite the enrofloxacin treatment. The minimal inhibitory concentration (MIC) of enrofloxacin for most of the re-isolated mycoplasmas was the same as that of the strain with which the birds were inoculated. Furthermore, no mutation could be detected in the fluoroquinolone target genes. These results suggest that M. gallisepticum can persist in chickens without development of resistance despite several treatments with enrofloxacin.